iBio, Inc. Company Profile
iBio, Inc. is a biopharmaceutical company commercializing its proprietary technology, the iBioLaunch™ platform, for the production of biologics including vaccines and therapeutic proteins. The iBioLaunch platform uses transient gene expression in green plants for superior efficiency in protein production. Advantages include significantly lower capital and process costs, and the technology is ideally suited to infectious disease applications where speed, scalability, and surge capacity are important. iBio’s strategy is to utilize its technology for development and manufacture of its own product candidates and work with both corporate and government clients to reduce their costs during product development and meet their needs for low cost, high quality biologics manufacturing systems. iBio owns technology developed at the Fraunhofer USA Center for Molecular Biotechnology, and continues to sponsor development and refinement of the technology for broad applications in human healthcare. Further information is available at www.ibioinc.com.
News Articles
iBio builds product base to match impressive list of backers
So far this year iBio has been steadily increasing its IP portfolio, having received patents for its technology, while also progressing products in clinical trials and revenues from early licensees of...
Ibio, GE Healthcare form patnership
GE Healthcare and Ibio have formed a partnership to commercialize plant-based technologies to manufacture biopharmaceuticals and vaccines.
Ibio, GE Healthcare form partnership
GE Healthcare and Ibio have formed a partnership to commercialize plant-based technologies to manufacture biopharmaceuticals and vaccines.
GE and iBio expand plant production alliance
GE Healthcare and iBio have forged an alliance to commercialise plant-based technologies for the manufacture of biologic drugs and vaccines. The two companies have worked together on the platform sinc...
GE Healthcare and iBio form new global alliance
GE Healthcare and iBio, a Newark, Del.-based provider of pharmaceutical product applications, have formed a new global alliance to commercialize plant-based technologies for the manufacture of biophar...
A few tidbits on the wires yesterday about new pharma facilities. Firstly, GE and iBio announced they are designing a new plant-cell based vaccine facility for a client pharma company. The identity of...
iBio and GE Healthcare form new global alliance
Biotechnology company iBio, self-professed leader in the plant-made pharmaceutical field, and GE Healthcare, the health business of General Electric, announced on 26 July 2012 a new global alliance to...
GE and iBio designing plant-cell based vaccine facility
GE Healthcare has started designing a vaccine manufacturing facility a drug company, just days after expanding its collaboration with plant-cell production technology firm iBio.
Drugs and Medications
None
PubMed Articles
None
Clinical Trials
None
Companies
What:
iBio, Inc. is a biopharmaceutical company commercializing its proprietary technology, the iBioLaunch™ platform, for the production of biologics including vaccines and therape...
IBIO is a life sciences industry association comprised of International agricultural and human health companies combating disease and malnutrition worldwide Established small and medium sized compani...
More Information about "iBio, Inc." on BioPortfolio
We have published hundreds of iBio, Inc. news stories on BioPortfolio along with dozens of iBio, Inc. Clinical Trials and PubMed Articles about iBio, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of iBio, Inc. Companies in our database. You can also find out about relevant iBio, Inc. Drugs and Medications on this site too.
